In this large, US claims-based retrospective study, we evaluated the 5-year prevalence of PNH among commercially insured patients and PNH-related HRU and direct costs associated with the C5 inhibitors, eculizumab and ravulizumab, among patients with PNH. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.